The Comparative Pathology and Mouse Phenotyping Shared Resource (CPMPSR) provides expert, readily available and affordable experimental pathology support to investigators utilizing animal models to study human cancer. Formeriy known as the Mouse Phenotyping Shared Resource (established in 2001), it has been extensively reorganized since the recruitment in September 2008 of Krista La Perle, D.V.M., Ph.D., from Memorial Sloan Kettering Cancer Center. Dr. La Perie is a board-certified veterinary pathologist and NIH-funded, postdoctoral alumna of OSU's Department of Veterinary Biosciences (VBS). The shared resource name change reflects the diverse species of animals utilized in varied projects conducted by OSUCCC members that evaluate therapeutic efficacy, chemoprevention and safety of novel therapeutics in rodent and non-rodent xenograft and metastasis models, while continuing to emphasize the phenotypic characterization of newly generated genetically engineered mice. Under Dr. La Perie's direction and strong institutional support, the laboratory was relocated, technical support was expanded, and a second, dedicated comparative pathologist is being recruited. All of these improvements are designed to improve the quality of comparative pathology support provided to OSUCCC members and address concerns of the 2004 CCSG review. Continued services include comprehensive macroscopic and microscopic examinations of various species of laboratory animals, including genetically engineered mice. Clinical pathology testing including hematology, clinical chemistry and urinalyses performed previously by the OSU Veterinary Teaching Hospital Clinical Pathology Laboratory are now conducted in-house on newly acquired analyzers by a dedicated medical laboratory technologist. The CPMPSR also utilizes reference laboratories for novel tests not performed in-house. Radiography is performed by the CPMPSR to enhance morphologic evaluations on post-mortem specimens. The CPMPSR works closely on serial, ante-mortem imaging and pathology correlates with the OSUCCC Imaging Shared Resource to assist investigators who need the wide array of ante-mortem imaging modalities offered by the OSUCCC. Preparation of routine frozen and paraffin slides, tissue microarrays and special histochemical and immunohistochemical staining previously performed by the VBS Histology and Immunohistochemistry Core is now integrated with the CPMPSR. An extensive menu of immunohistochemical antibodies specifically for use on rodent tissues has been established. Tissue microarrays incorporating tumors from various mouse models of cancer have also been prepared. The CPMPSR provides a referral service to experienced scientists within the OSU research community providing expertise in animal model development, experimental design, optimal sample collection and data interpretation. The CPMPSR is utilized by all six OSUCCC Scientific Programs and OSUCCC members account for more than 60% of all users. The CPMPSR leverages extensive institutional support, and seeks only 25.6% support from CCSG funds. The service contributes critical support to high quality cancer relevant publications and the education and training of future cancer investigators.
Comparative pathologists affiliated with the CPMPSR are experts with normal anatomy and physiology, as well as rodent pathology and background age- and strain/breed-related lesions of various animal models Recognition of lesions and their interpretation in the context of individual investigations provides a critical and integrated component to cancer research incorporating animals to model cancer and assist in the development of treatment in humans.
|Fazio, Nicola; Buzzoni, Roberto; Baudin, Eric et al. (2016) A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. Anticancer Res 36:713-9|
|Eloy, Josimar O; Petrilli, Raquel; Topan, JosÃ© Fernando et al. (2016) Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy. Colloids Surf B Biointerfaces 141:74-82|
|Byrd, John C; Flynn, Joseph M; Kipps, Thomas J et al. (2016) Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood 127:79-86|
|Datta, Jharna; Islam, Mozaffarul; Dutta, Samidha et al. (2016) Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs. Oral Oncol 56:32-9|
|Wang, Hai; Agarwal, Pranay; Zhao, Shuting et al. (2016) Combined cancer therapy with hyaluronan-decorated fullerene-silica multifunctional nanoparticles to target cancer stem-like cells. Biomaterials 97:62-73|
|Villalona-Calero, Miguel A; Duan, Wenrui; Zhao, Weiqiang et al. (2016) Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. J Natl Cancer Inst 108:|
|Rai, K; Pilarski, R; Cebulla, C M et al. (2016) Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet 89:285-94|
|Kerrigan, Kathleen; Shoben, Abigail; Otterson, Gregory (2016) Treatment of Lung Cancer Patients With Actionable Mutations in the Intensive Care Unit. Clin Lung Cancer 17:523-527|
|DiSilvestro, David J; Melgar-Bermudez, Emiliano; Yasmeen, Rumana et al. (2016) Leptin Production by Encapsulated Adipocytes Increases Brown Fat, Decreases Resistin, and Improves Glucose Intolerance in Obese Mice. PLoS One 11:e0153198|
|Terakawa, Jumpei; Rocchi, Altea; Serna, Vanida A et al. (2016) FGFR2IIIb-MAPK Activity Is Required for Epithelial Cell Fate Decision in the Lower MÃ¼llerian Duct. Mol Endocrinol 30:783-95|
Showing the most recent 10 out of 1929 publications